Severely Ill COVID-19 Patients May Exhibit Hypercoagulability Despite Escalated Anticoagulation.

ABSTRACT: Introduction: Severely ill COVID-19 patients receiving prophylactic-dose anticoagulation exhibit high rates of thrombosis and mortality. The escalation of anticoagulation also does not reduce mortality and has an uncertain impact on thrombosis rates. The reasons why escalated doses fail to outperform prophylactic doses in reducing risks of thrombosis and death in severely ill COVID-19 patients remain unclear. We hypothesized that escalated anticoagulation would not effectively prevent hypercoagulability and, consequently, would not reduce the risk of thrombosis and death in some severely ill patients. Methods: We conducted a prospective multicenter study that enrolled 3860 COVID-19 patients, including 1654 severely ill. They received different doses of low-molecular-weight or

SUBMITTER: Shakhidzhanov S 

PROVIDER: S-EPMC11943368 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature